Cancer-associated thrombosis: the when, how and why

Caio J Fernandes, Luciana T K Morinaga, José L Alves Jr, Marcela A Castro, Daniela Calderaro, Carlos V P Jardim, Rogerio Souza, Caio J Fernandes, Luciana T K Morinaga, José L Alves Jr, Marcela A Castro, Daniela Calderaro, Carlos V P Jardim, Rogerio Souza

Abstract

Cancer-associated thrombosis (CAT) is a condition in which relevance has been increasingly recognised both for physicians that deal with venous thromboembolism (VTE) and for oncologists. It is currently estimated that the annual incidence of VTE in patients with cancer is 0.5% compared to 0.1% in the general population. Active cancer accounts for 20% of the overall incidence of VTE. Of note, VTE is the second most prevalent cause of death in cancer, second only to the progression of the disease, and cancer is the most prevalent cause of deaths in VTE patients. Nevertheless, CAT presents several peculiarities that distinguish it from other VTE, both in pathophysiology mechanisms, risk factors and especially in treatment, which need to be considered. CAT data will be reviewed in this review.

Conflict of interest statement

Conflict of interest: C.J. Fernandes reports personal fees from Actelion, GSK and Bayer, outside the submitted work. Conflict of interest: L.T.K. Morinaga reports personal fees from Bayer, outside the submitted work. Conflict of interest: J.L. Alves Jr reports personal fees from Bayer and Actelion, outside the submitted work. Conflict of interest: M.A. Castro has nothing to disclose. Conflict of interest: D. Calderaro reports personal fees from Pfizer and Bayer, outside the submitted work. Conflict of interest: C.V.P. Jardim reports personal fees from Bayer and Actelion, and other funding from GSK (former employee), outside the submitted work. Conflict of interest: R. Souza reports personal fees from Actelion, GSK, Pfizer and Bayer, outside the submitted work.

Copyright ©ERS 2019.

References

    1. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Thromb Haemost 2014; 112: 843–852.
    1. Fernandes CJCDS, Jardim CVP, Alves JL Jr, et al. . Reperfusion in acute pulmonary thromboembolism. J Bras Pneumol 2018; 44: 237–243.
    1. Elyamany G, Alzahrani AM, Bukhary E. Cancer-associated thrombosis: an overview. Clin Med Insights Oncol 2014; 8: 129–137.
    1. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis 2016; 41: 3–14.
    1. Laporte S, Mismetti P, Decousus H, et al. . Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 2008; 117: 1711–1716.
    1. Puurunen MK, Gona PN, Larson MG, et al. . Epidemiology of venous thromboembolism in the Framingham Heart Study. Thromb Res 2016; 145: 27–33.
    1. Turpie AGG, Haas S, Weitz JI, et al. . GARFIELD-VTE: 6-month outcomes. Res Pract Thromb Haemost 2017; 1: 1–15.
    1. Khorana AA, Francis CW, Culakova E, et al. . Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632–634.
    1. Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol 2018; 72: 89–93.
    1. Blann AD, Lip GY. Venous thromboembolism. BMJ 2006; 332: 215–219.
    1. Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract 2011; 2011: 394740.
    1. Ades S, Kumar S, Alam M, et al. . Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer. J Thromb Haemost 2015; 13: 998–1003.
    1. Corrales-Rodriguez L, Soulieres D, Weng X, et al. . Mutations in NSCLC and their link with lung cancer-associated thrombosis: a case–control study. Thromb Res 2014; 133: 48–51.
    1. Nielsen C, Birgens HS, Nordestgaard BG, et al. . The JAK2V617F somatic mutation, mortality and cancer risk in the general population. Haematologica 2011; 96: 450–453.
    1. Shetty S, Kulkarni B, Pai N, et al. . JAK2 mutations across a spectrum of venous thrombosis cases. Am J Clin Pathol 2010; 134: 82–85.
    1. Stein PD, Beemath A, Meyers FA, et al. . Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119: 60–68.
    1. Fernandes C. Evolution in the management of non-small cell lung cancer in Brazil. J Bras Pneumol 2017; 43: 403–404.
    1. Gade IL, Braekkan SK, Naess IA, et al. . The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort. J Thromb Haemost 2017; 15: 1567–1575.
    1. Blom JW, Doggen CJ, Osanto S, et al. . Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–722.
    1. Trujillo-Santos J, Nieto JA, Tiberio G, et al. . Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 435–439.
    1. Walker AJ, Card TR, West J, et al. . Incidence of venous thromboembolism in patients with cancer – a cohort study using linked United Kingdom databases. Eur J Cancer 2013; 49: 1404–1413.
    1. Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie 2012; 32: 115–125.
    1. Imberti D, Benedetti R. Primary prophylaxis of VTE in cancer outpatients. Thromb Res 2016; 140: Suppl 1, S103–S108.
    1. Khorana AA, Kuderer NM, Culakova E, et al. . Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902–4907.
    1. Ay C, Dunkler D, Marosi C, et al. . Prediction of venous thromboembolism in cancer patients. Blood 2010; 116: 5377–5382.
    1. Khorana AA, McCrae KR. Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res 2014; 133: Suppl 2, S35–S38.
    1. Agnelli G, Gussoni G, Bianchini C, et al. . Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10: 943–949.
    1. Agnelli G, George DJ, Kakkar AK, et al. . Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366: 601–609.
    1. Di Nisio M, Porreca E, Candeloro M, et al. . Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 2016; 12: CD008500.
    1. Carrier M, Abou-Nassar K, Mallick R, et al. . Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380: 711–719.
    1. Prandoni P, Bernardi E, Valle FD, et al. . Extensive computed tomography versus limited screening for detection of occult cancer in unprovoked venous thromboembolism: a multicenter, controlled, randomized clinical trial. Semin Thromb Hemost 2016; 42: 884–890.
    1. Robin P, Le Roux PY, Planquette B, et al. . Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncol 2016; 17: 193–199.
    1. Kearon C, Akl EA, Ornelas J, et al. . Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149: 315–352.
    1. Prandoni P, Lensing AW, Piccioli A, et al. . Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484–3488.
    1. Meyer G, Marjanovic Z, Valcke J, et al. . Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729–1735.
    1. Lee AY, Levine MN, Baker RI, et al. . Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153.
    1. Lee AYY, Kamphuisen PW, Meyer G, et al. . Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314: 677–686.
    1. Hakoum MB, Kahale LA, Tsolakian IG, et al. . Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev 2018; 1: CD006649.
    1. Akl EA, Kahale L, Barba M, et al. . Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2014; 7: CD006650.
    1. Francis CW, Kessler CM, Goldhaber SZ, et al. . Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 2015; 13: 1028–1035.
    1. Fernandes CJ, Alves Junior JL, Gavilanes F, et al. . New anticoagulants for the treatment of venous thromboembolism. J Bras Pneumol 2016; 42: 146–154.
    1. Xavier FD, Hoff PMG, Braghiroli MI, et al. . Rivaroxaban: an affordable and effective alternative in cancer-related thrombosis? J Glob Oncol 2017; 3: 15–22.
    1. Pignataro BS, Nishinari K, Cavalcante RN, et al. . Oral rivaroxaban for the treatment of symptomatic venous thromboembolism in 400 patients with active cancer: a single-center experience. Clin Appl Thromb Hemost 2017; 23: 883–887.
    1. Vedovati MC, Germini F, Agnelli G, et al. . Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147: 475–483.
    1. Raskob GE, van Es N, Verhamme P, et al. . Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378: 615–624.
    1. Kraaijpoel N, Di Nisio M, Mulder FI, et al. . Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study. Thromb Haemost 2018; 118: 1439–1449.
    1. Young AM, Marshall A, Thirlwall J, et al. . Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36: 2017–2023.
    1. Agnelli G, Becattini C, Bauersachs R, et al. . Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio Study. Thromb Haemost 2018; 118: 1668–1678.
    1. Khorana AA, Noble S, Lee AYY, et al. . Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16: 1891–1894.
    1. Saba HI, Khalil FK, Morelli GA, et al. . Thromboembolism preceding cancer: a correlation study. Am J Hematol 2003; 72: 109–114.
    1. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 2000; 342: 1953–1958.
    1. Carrier M, Le Gal G, Wells PS, et al. . Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med 2008; 149: 323–333.
    1. Carrier M, Lazo-Langner A, Shivakumar S, et al. . Screening for occult cancer in unprovoked venous thromboembolism. N Engl J Med 2015; 373: 697–704.
    1. Prandoni P, Casiglia E, Piccioli A, et al. . The risk of cancer in patients with venous thromboembolism does not exceed that expected in the general population after the first 6 months. J Thromb Haemost 2010; 8: 1126–1127.
    1. Coyle K, Carrier M, Lazo-Langner A, et al. . Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thromb Res 2017; 151: 67–71.
    1. Delluc A, Antic D, Lecumberri R, et al. . Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2017; 15: 2076–2079.
    1. Robin P, Le Roux PY, Tromeur C, et al. . Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thromb Res 2017; 159: 48–51.
    1. van Es N, Le Gal G, Otten HM, et al. . Screening for occult cancer in patients with unprovoked venous thromboembolism: a systematic review and meta-analysis of individual patient data. Ann Intern Med 2017; 167: 410–417.
    1. Jara-Palomares L, Otero R, Jimenez D, et al. . Development of a risk prediction score for occult cancer in patients with VTE. Chest 2017; 151: 564–571.
    1. Klok FA, Huisman MV. Management of incidental pulmonary embolism. Eur Respir J 2017; 49: 1700275.
    1. Shinagare AB, Okajima Y, Oxnard GR, et al. . Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism. Lung Cancer 2012; 78: 161–166.
    1. Sun JM, Kim TS, Lee J, et al. . Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy. Lung Cancer 2010; 69: 330–336.
    1. Lyman GH, Bohlke K, Khorana AA, et al. . Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol 2015; 33: 654–656.
    1. Watson HG, Keeling DM, Laffan M, et al. . Guideline on aspects of cancer-related venous thrombosis. Br J Haematol 2015; 170: 640–648.
    1. Mandala M, Falanga A, Roila F, et al. . Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22: Suppl 6, vi85–vi92.
    1. Napolitano M, Saccullo G, Malato A, et al. . Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. J Clin Oncol 2014; 32: 3607–3612.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj